Abstract:Objectives Human papillomavirus type 16 (HPV16) is a major causative agent of cervical cancer, necessitating the development of innovative therapeutic strategies. This Phase 1 clinical trial aimed to evaluate the safety and preliminary efficacy of a novel intervention against persistent HPV16 infection and associated cervical lesions, utilizing an interferon-inducing viral vector expressing tumor antigens (delNS/E6E7), in a placebo-controlled study involving 28 patients. Methods In this placebo-controlled Phase 1 trial, 28 participants with HPV16 infection and cervical lesions were randomly assigned in a 3:1 ratio to receive the interferon-inducing viral vector delNS/E6E7 or a placebo over a 12-week period. Safety assessments were conducted regularly throughout the trial, and efficacy was evaluated by monitoring changes in HPV16 infection and cervical lesion status. Results The intervention group, which received delNS/E6E7, exhibited a favorable safety profile, with only mild and moderate transient adverse events reported. No serious adverse events related to the treatment were observed. Early indications of efficacy, such as HPV 16 clearance and regression or stabilization of cervical lesions were observed. The 12 month period of the follow-up study is still ongoing. Conclusions Conclusion: In this placebo-controlled Phase 1 trial, the interferon-inducing viral vector delNS/E6E7 exhibited a favorable safety profile and early indications of efficacy for the treatment of HPV16 infection and associated cervical lesions. These findings emphasize the potential of this innovative treatment approach for HPV16-related cervical health issues and underscore the need for further investigation in larger, randomized, controlled trials. Conflicts of Interest F. Groiss, T. Muster and C. Nicolodi are working for the company, which is producing the immune therapy (Blue Sky GmbH, Vienna, Austria). M. Bayerle-Eder is consultant of Blue Sky GmbH.

(185) Safety And Preliminary Efficacy Of Phase 1 Trial Targeting Hpv16 Infection And Cervical Lesions With Interferon-Inducing Viral Vector Delns/E6E7: A Placebo-Controlled Study With 28 Patients